8-K: PDS Biotech Gains FDA Alignment for Phase 3 Trial of Versamune HPV in Head and Neck Cancer

PDS Biotechnology has received FDA agreement on the design of its Phase 3 clinical trial for Versamune HPV in HPV16-positive head and neck cancer, with the trial expected to begin in Q4 2024.

Summary

• PDS Biotechnology has announced that it has received official minutes from its meeting with the FDA regarding the next steps for its Phase 3 clinical trial of Versamune HPV for HPV16-positive head and neck squamous cell carcinoma.
• The company will initiate the Phase 3 VERSATILE-003 trial in Q4 2024.
• The FDA has supported the development of both double and triple combinations of Versamune HPV with other therapies.
• The initial part of the study will involve dose optimization of PDS01ADC in the triple combination.
• The FDA agreed that the dose optimization should be done separately to avoid delays in the randomized trial of the double combination.
• The primary endpoint of the VERSATILE-003 trial is overall survival.
• The company has engaged a clinical research organization and is advancing preparatory work to begin enrollment.
• The company presented data from the VERSATILE-002 study and proposed an updated design for the Phase 3 trial, including updated statistical endpoints based on recent survival data.

Sentiment

Score: 8

Explanation: The document is highly positive due to the FDA alignment, promising clinical trial results, and the initiation of a Phase 3 trial. The company's technology appears to be effective and well-tolerated, and the management commentary is optimistic. However, the need for additional financing and the inherent risks of clinical trials temper the sentiment slightly.

Positives

• The FDA has supported the company's strategy for both double and triple combinations of Versamune HPV.
• The company has received Fast Track designation for the Versamune HPV + pembrolizumab combination.
• The VERSATILE-002 study showed promising survival data, with a median overall survival of 30 months.
• The company has strong key opinion leader support for the VERSATILE-003 trial.
• The company has lined up a significant number of target sites for the trial.
• The company has observed a 77.4% disease control rate in the VERSATILE-002 study.
• The company has observed 21% of patients in the VERSATILE-002 study had 90-100% tumor shrinkage.

Negatives

• The company needs to conduct a separate dose optimization study for PDS01ADC, which could potentially delay the triple combination arm of the trial.
• The company is dependent on additional financing to fund its operations and complete the development and commercialization of its product candidates.

Risks

• The company's ability to protect its intellectual property rights is a risk.
• The company's anticipated capital requirements and cash runway are subject to uncertainty.
• The company is dependent on additional financing to fund its operations.
• The company has a limited operating history in its current line of business.
• The timing and success of planned clinical trials are subject to uncertainty.
• The company's interpretation of research and development results may not guarantee future success.
• The company's ability to continue as a going concern is a risk.
• Legislative, regulatory, political, and economic developments not within the company's control could impact results.

Future Outlook

The company plans to initiate the Phase 3 VERSATILE-003 trial in Q4 2024 and is working towards advancing its lead program in advanced HPV16-positive head and neck squamous cell cancers. The company also plans to continue development of its Versamune and Infectimune platforms.

Management Comments

• We appreciate the FDAs support in the development of both the double and triple Versamune HPV-based combinations, said Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech.
• We are also pleased to have aligned on initiating the updated VERSATILE-003 study.
• The VERSATILE-002 results have matured significantly and positively over the last year, allowing us to revise the statistical endpoints of the study to provide additional robustness to the study design.
• We continue to believe that the combination, based on encouraging survival, disease control response rates and safety has the potential to significantly advance the treatment of HPV16-positive HNSCC.
• Our goal now is to investigate Versamune HPV + pembrolizumabs potential as the first targeted immunotherapy for HPV16-positive HNSCC.
• The addition of PDS01ADC in the future has the potential to provide further clinical benefit to an effective targeted immunotherapy.
• Our VERSATILE-003 trial has significant key opinion leader support, including from the investigators involved in VERSATILE-002, and we have lined up a significant number of the target sites that have indicated strong interest in participating in the trial, said Kirk Shepard, MD, Chief Medical Officer.

Industry Context

This announcement is significant as it represents a key step forward in the development of a potential new treatment option for HPV16-positive head and neck cancer, an area with significant unmet medical need. The company is positioning its Versamune HPV therapy as a potential first targeted immunotherapy for this indication.

Comparison to Industry Standards

• The median overall survival of 30 months observed in the VERSATILE-002 study with Versamune HPV plus pembrolizumab compares favorably to the 12.3 to 14.9 months reported for pembrolizumab alone in the KEYNOTE-048 study for patients with a CPS score of 1.
• The company's 34% confirmed objective response rate (ORR) in the VERSATILE-002 study for patients with a CPS score of 1 is higher than the 19% ORR reported for pembrolizumab alone in the KEYNOTE-048 study for the same patient population.
• The company's 48% confirmed objective response rate (ORR) in the VERSATILE-002 study for patients with a CPS score of 20 is higher than the 23% ORR reported for pembrolizumab alone in the KEYNOTE-048 study for the same patient population.
• The company's 77.4% disease control rate in the VERSATILE-002 study is a positive indicator of the therapy's potential effectiveness.
• The company's data suggests that Versamune HPV induces the right type and quantity of potent tumor targeting memory T cells that promote patient survival, which is a key differentiator from other therapies.

Stakeholder Impact

• Shareholders will be positively impacted by the progress in clinical development and the potential for a new treatment option.
• Patients with HPV16-positive head and neck cancer may benefit from a new treatment option.
• Employees will be involved in the execution of the Phase 3 trial and the continued development of the company's technology.

Next Steps

• The company will initiate the Phase 3 VERSATILE-003 clinical trial in Q4 2024.
• The company will conduct a dose optimization study for PDS01ADC.
• The company will continue to advance its research and development programs.

Key Dates

Keywords

Versamune HPV, PDS01ADC, immunotherapy, head and neck cancer, HPV16, clinical trial, FDA, pembrolizumab, T cell, cancer